Effect of Apoaequorin on Cognitive Function in Aged Canines.
Madison, WI (Vocus) October 7, 2010
Quincy Bioscience, a research-based biotechnology company, announced results from the study, “Effect of Apoaequorin on Cognitive Function in Aged Canines.” The trial was conducted by CanCog Technologies, Inc., one of the world’s leading cognitive research organizations specializing in age-dependent cognitive decline and neuropathology research for human and canine cognitive assessment.
In the blinded study, dogs received either apoaequorin or a control orally in a chewable tablet form. The dogs in the apoaequorin group significantly outperformed the control group in three separate tasks which measure cognitive abilities.
The data is not only positive for canines but also important for humans. Like people, aged dogs can develop cognitive dysfunction syndrome, a form of dementia which can be seen in an aged dog’s inability to learn new tasks and show deficits in visuospatial memory, or the ability to remember the location of objects. Additionally, brain aging in dogs has been shown to be accompanied by loss of brain cells in the cortical and frontal lobe region, which also occurs in human aging.
In the study, twenty-four beagles at least nine years old were assigned to three cognitively equivalent groups and received placebo or two different doses of the jellyfish protein apoaequorin. The dogs were tested using standardized canine cognitive testing methods, including: object discrimination, visual search task, and a visuospatial working memory task.
The treatment groups outperformed the control groups in each of the three tasks, with learning and visual search tasks reaching statistical significance. The study team, lead by Bill Milgram, Ph.D. concluded, “Overall, these results suggest that daily administration of apoaequorin has beneficial effects seen in improved learning and in attention. All of the animals tested in the study were aged, and showed some degree of cognitive impairment. Thus, one possible interpretation is that the treatment has the potential of reversing age-associated cognitive dysfunction.”
Quincy Bioscience, which launched Quincy Animal Health this past year, plans to use the data to support the launch of its first product this fall – a supplement as an aid in the treatment of canine cognitive dysfunction syndrome.
Apoaequorin has demonstrated neuroprotection in pre-clinical studies performed at the University of Wisconsin-Milwaukee. Apoaequorin was originally isolated from Aequorea victoria, a species of jellyfish found in the Puget Sound.
About Quincy Bioscience
Quincy Bioscience is a biotechnology company based in Madison, Wisconsin. Quincy Bioscience is focused on the discovery, development and commercialization of novel compounds to fight the aging process. The company's products focus on restoring calcium balance related to neurodegenerative disorders and other destructive age-related mechanisms.